Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Abeona Therapeutics Inc.NASDAQ: ABEO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $20.74M (cash outflow) rose 4.7% year over year, behind the +35.3% change in trailing-twelve-month free cash flow. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +24.6% a year.
Context
- Free cash flow amounted to 1448.5% of revenue in FY2025.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +4.7% toward the trailing-twelve-month pace of +35.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (84.3M) USD
- Year-over-year change
- -44.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (84.3M) | -44.2% |
| FY2024 | 2024-12-31 | (58.46M) | -56.6% |
| FY2023 | 2023-12-31 | (37.34M) | +14.4% |
| FY2022 | 2022-12-31 | (43.61M) | +37.5% |
| FY2021 | 2021-12-31 | (69.82M) | — |
Free Cash Flow vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 free cash flow of $85.24M is the 4th largest of the 10 companies compared; the peer median is $64.63M.
- Its year-over-year change of +35.3% is the 2nd highest of 10, against a peer median of -8.8%.
- Free cash flow amounts to 586.2% of revenue for ABEO, versus a peer median of 309.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $129.94M | +14.0% | +108.0% | 356.1% | |
| LTM Mar 2026 | $102.38M | +1.6% | +13.6% | 5078.2% | |
| LTM Mar 2026 | $87.42M | -8.8% | — | 309.7% | |
| LTM Mar 2026 | $85.24M | +35.3% | +24.6% | 586.2% | |
| LTM Mar 2026 | $68.89M | +26.2% | +29.9% | — | |
| LTM Mar 2026 | $64.63M | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $58.89M | -34.5% | — | 129.9% | |
| LTM Mar 2026 | $53.6M | +72.0% | — | 23.6% | |
| LTM Mar 2026 | $39.84M | -29.1% | -21.3% | 56.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $39.73M | -21.7% | +23.1% | — |
| Peer median (excluding ABEO) | $64.63M | -8.8% | +18.4% | 309.7% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.92M | 3.05M | 4.77M | 6.63M | 10.78M |
| Change in Working Capital | (18.26M) | (5.89M) | (1.79M) | (4.38M) | (5.39M) |
| Accounts Receivables | (3M) | 2.81M | (2.04M) | 792K | (5.06M) |
| Inventory | 0 | 0 | 0 | 0 | (5.49M) |
| Accounts Payables | (15.59M) | (9.11M) | 2.04M | (3.49M) | 6.54M |
| Other Working Capital | 324K | 404K | (3.83M) | (1.68M) | (1.37M) |
| Other Non-Cash Items | 24.15M | (5.52M) | 11M | 2.57M | (156.46M) |
| Operating Cash Flow | (65.67M) | (43.48M) | (37.01M) | (56.02M) | (76.33M) |
| Capital Expenditures | (4.15M) | (130K) | (331K) | (2.45M) | (7.98M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.16M) | (78.21M) | (51.64M) | (157.01M) | (206.63M) |
| Sales of Investments | 90.38M | 52.64M | 51.97M | 120.2M | 167.27M |
| Other Investing Activities | 0 | 1.73M | 204K | 18K | 152.37M |
| Investing Cash Flow | 66.06M | (23.96M) | 208K | (39.24M) | 105.03M |
| Debt Repayment | 0 | 0 | 0 | 20M | 0 |
| Common Stock Issued | 24.03M | 46.96M | 37.39M | 85.63M | 26.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 831K | (5K) | (332K) | (1.49M) | (37K) |
| Financing Cash Flow | 24.86M | 43.17M | 37.06M | 104.14M | 26.04M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.26M | (24.27M) | 256K | 8.88M | 54.74M |
| Free Cash Flow | (69.82M) | (43.61M) | (37.34M) | (58.46M) | (84.3M) |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.